IRIS UniCatt

Pera, Maria Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.127
EU - Europa 1.901
AS - Asia 1.274
SA - Sud America 308
AF - Africa 35
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.077
SG - Singapore 514
IT - Italia 492
SE - Svezia 411
CN - Cina 351
BR - Brasile 275
IE - Irlanda 212
DE - Germania 180
FR - Francia 144
ID - Indonesia 99
RU - Federazione Russa 81
GB - Regno Unito 79
IN - India 75
KR - Corea 66
FI - Finlandia 63
TR - Turchia 32
NL - Olanda 31
CA - Canada 27
HK - Hong Kong 27
CZ - Repubblica Ceca 24
UA - Ucraina 22
BE - Belgio 21
ES - Italia 20
AT - Austria 18
IR - Iran 17
IL - Israele 16
MK - Macedonia 13
PL - Polonia 13
RO - Romania 13
CH - Svizzera 12
JP - Giappone 12
AR - Argentina 10
CI - Costa d'Avorio 10
PA - Panama 10
BD - Bangladesh 9
MX - Messico 9
RS - Serbia 9
CO - Colombia 8
EG - Egitto 8
IQ - Iraq 8
PT - Portogallo 8
MA - Marocco 7
PK - Pakistan 6
HR - Croazia 5
LT - Lituania 5
SA - Arabia Saudita 5
VN - Vietnam 5
DK - Danimarca 4
GR - Grecia 4
LU - Lussemburgo 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BO - Bolivia 3
CL - Cile 3
DO - Repubblica Dominicana 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PE - Perù 3
UZ - Uzbekistan 3
VE - Venezuela 3
AL - Albania 2
AU - Australia 2
BG - Bulgaria 2
BT - Bhutan 2
EE - Estonia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
TH - Thailandia 2
TW - Taiwan 2
UY - Uruguay 2
ZM - Zambia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
GL - Groenlandia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
MT - Malta 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
QA - Qatar 1
SC - Seychelles 1
SI - Slovenia 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.652
Salva come PNG Salva come JPEG
Città #
Chandler 460
Singapore 320
Ashburn 315
Dublin 193
New York 138
Rome 127
Jakarta 98
Milan 83
Hefei 65
Seoul 65
Los Angeles 54
Helsinki 46
Boston 44
Marseille 44
Moscow 42
San Mateo 38
Princeton 36
Pune 34
Chicago 32
Nuremberg 30
The Dalles 27
São Paulo 26
Frankfurt am Main 23
Hong Kong 22
Munich 22
Ann Arbor 21
Dearborn 19
London 19
Wilmington 19
Düsseldorf 18
Nanjing 18
Palermo 18
Bremen 17
Brussels 17
Brno 16
Paris 16
Seattle 15
Falkenstein 14
Toronto 14
Boardman 13
Hyderabad 13
Beijing 12
Portsmouth 12
Shanghai 12
Cattolica 11
Columbus 11
Jacksonville 11
Redwood City 11
Abidjan 10
Andover 10
Belo Horizonte 10
Council Bluffs 10
Houston 10
Skopje 10
Augusta 9
Edinburgh 9
Kish 9
Rio de Janeiro 9
Santa Clara 9
Vienna 9
Amsterdam 8
Fairfield 8
Turin 8
Washington 8
Bari 7
Brasília 7
Changsha 7
Lancaster 7
Madrid 7
Redmond 7
San Francisco 7
Busto Arsizio 6
Cairo 6
Jiaxing 6
Menlo Park 6
Mexico City 6
Niš 6
Shenyang 6
Turku 6
Bexley 5
Bologna 5
Campinas 5
Dhaka 5
Hangzhou 5
Hebei 5
Jinan 5
Lawrence 5
Leawood 5
Lisbon 5
Montreal 5
Mountain View 5
Norwalk 5
Olomouc 5
Ottawa 5
Salvador 5
Secaucus 5
Warsaw 5
Zagreb 5
Atlanta 4
Barcelona 4
Totale 3.077
Salva come PNG Salva come JPEG
Nome #
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 132
Revised upper limb module for spinal muscular atrophy: Development of a new module 111
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 109
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 102
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 102
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 102
Predominant distal muscle involvement in spinal muscular atrophy 98
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 92
Developmental milestones in type I spinal muscular atrophy 91
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 88
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 87
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 86
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 86
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 85
Assessing floppy infants: a new module 85
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 82
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 82
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 79
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 79
Developmental milestones in type I spinal muscular atrophy 79
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 78
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 77
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 77
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 76
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 75
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 74
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 74
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 73
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 72
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 70
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 68
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 67
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 67
Clinical Variability in Spinal Muscular Atrophy Type III. 65
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 65
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 64
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 64
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 63
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 63
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 62
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 61
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 61
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 61
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 61
Development of an academic disease registry for spinal muscular atrophy 60
Revised upper limb module for spinal muscular atrophy: Development of a new module 57
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 55
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 53
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 52
Risdiplam in Type 1 Spinal Muscular Atrophy 52
Revised upper limb module for spinal muscular atrophy: 12 month changes 51
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 51
Sleep disorders in spinal muscular atrophy 50
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 49
Longitudinal natural history of type I spinal muscular atrophy: A critical review 48
Gain and loss of abilities in type II SMA: A 12-month natural history study 48
Early treatment of type II SMA slows rate of progression of scoliosis 47
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 47
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 46
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 45
Spinal muscular atrophy — insights and challenges in the treatment era 45
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 43
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 43
An observational study of functional abilities in infants, children, and adults with type 1 SMA 43
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 43
Long term follow-up of scoliosis progression in type II SMA patients 42
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 41
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 39
New therapies for spinal muscular atrophy: where we stand and what is next 39
Old measures and new scores in spinal muscular atrophy patients 39
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 38
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 38
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 38
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 38
Neonatal hypotonia and neuromuscular conditions 37
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 35
An observational study of functional abilities in infants, children, and adults with type 1 SMA 35
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 35
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 34
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 34
Early neurodevelopmental assessment in Duchenne muscular dystrophy 33
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 33
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 33
Risdiplam in Type 1 Spinal Muscular Atrophy 32
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 32
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 32
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 32
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 31
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 31
Sudden and isolated Broca's aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children 29
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 29
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study 29
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 27
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 26
SFP CO-31 - Inflammatory optic neuritis: Course and prognostic factors in 102 children|SFP CO-31 - Névrites optiques inflammatoires: évolution et facteurs pronostiques chez 102 enfants 25
Development of an academic disease registry for spinal muscular atrophy 23
MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients 22
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 21
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 21
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 20
Totale 5.646
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 0 4
2020/202170 2 6 1 3 5 7 8 1 12 5 18 2
2021/2022449 30 6 5 63 34 13 9 63 33 27 70 96
2022/20231.628 108 174 108 222 108 201 102 167 250 36 88 64
2023/20241.318 40 265 49 136 49 242 142 59 18 68 110 140
2024/20252.043 49 42 157 114 193 125 102 96 332 203 535 95
Totale 5.751